OUR MEDICINES
ViiV Healthcare remains committed to developing and investing in new medicines and innovations that aim to improve the treatment success and quality of life of all people living with HIV.
We hope you find the ViiV Exchange a valuable resource to learn more about our current medicines, clinical data and prescribing information.
Apretude (cabotegravir) long-acting for PrEP is indicated in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 in high-risk adults and adolescents, weighing at least 35 kg.
Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Cabotegravir in combination with rilpivirine is indicated for treatment of HIV-1 in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior failure with, agents of NNRTI and INI class.
Indicated for adults with multidrug resistant HIV-1 infection (in combination with other ARVs) for whom it is otherwise not possible to construct a suppressive antiviral regimen.
Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
Triumeq (dolutegravir/ abacavir/ lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children weighing at least 25 kg.
Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
Triumeq (dolutegravir/abacavir/lamivudine) is indicated for the treatment of HIV in children who weigh at least 14 kg and less than 25 kg. Screening for HLA-B*5701 should be performed prior to use.
Do not use if HLA-B*5701 positive.
Tivicay (dolutegravir) 10/25/50 mg film-coated tablets are indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age or older and weighing at least 14kg.
Tivicay (dolutegravir) 5 mg dispersible tablets are indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
PM-GB-HVU-WCNT-230001 | June 2024
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
